Spain Brain Cancer Therapeutics Market

Spain Brain Cancer Therapeutics Market Executive Summary

Spain Brain Cancer Therapeutics Market valued at $44 Mn in 2022, projected to reach $92 Mn by 2030 with a 9.6% CAGR.

The abnormal proliferation of brain cells serves as an indication of brain cancer, where these cells exhibit characteristics that can be either malignant (cancerous) or benign (non-cancerous). While the exact cause of brain cancer remains unclear, identified risk factors include exposure to ionizing radiation and a family history of brain tumors. Common symptoms associated with a brain tumor include headaches, gradual sensory decline, issues with balance, speech impediments, and hearing difficulties. The manifestation of these symptoms varies depending on factors such as the tumor’s size, location, and growth rate. Treatment approaches for brain cancer are determined by the tumor’s type, location, and size, with frequently utilized methods including radiosurgery, chemotherapy, radiotherapy, surgery, and the use of carmustine implants.

In Spain, brain tumors are relatively common, coming in at number 17 in incidence and number 11 in fatality. The projected number of new cases in 2020 was 4,420 across all age groups, including 1,133 cases in children (0–14 years old) and 564 cases in young people (15–39 years old). The predicted 5-year prevalence of all primary brain and central nervous system (CNS) cancers in Spain was 131,668 as of December 31, 2019. Meningioma was the most common kind among specialized types, it accounted for almost one-third of all cases and was benign in 99% of cases. Astrocytoma was a notable malignant brain tumor that mostly affected children, whereas glioblastoma, the most prevalent malignant brain tumor in adults, made up about 14.6% of all primary brain and CNS malignancies.

Glioblastoma is the most aggressive type of brain cancer. Researchers from the University of Lleida and the Institute for Research in Biomedicine of Lleida have discovered a novel cell death pathway in this disease. Mibefradil, a medication once used to treat hypertension, and its counterpart NNC-55-0396 were found to be effective in destroying glioblastoma cells and slowing the growth of tumors in mice. Remarkably, it was discovered that the anti-tumor action functions via another signaling mechanism, refuting earlier theories regarding T-channel blocking. This finding establishes the foundation for additional clinical trials, especially with NNC-55-0396 in glioblastoma patients, and highlights the possibility of repurposing currently available medications for the treatment of cancer. Simultaneously, Laminar Pharma, a biopharmaceutical pioneer in Spain, is committed to revolutionizing the treatment of brain cancer.

Market Dynamics

Market Growth Drivers

Increasing Incidence of Brain Cancer: Unfortunately, brain cancer is becoming more common in Spain, especially in the older population. Gliomas, the most common kind of brain tumor, are predicted to rise significantly by 2030. Spain is ranked 17th in the world for the incidence of brain tumors and 11th in terms of fatalities. The increasing incidence of brain cancer highlights the urgent need for efficient treatment alternatives, which in turn fuels the market's innovations to meet the nation's expanding needs for brain cancer-related healthcare.

Increasing Awareness and Advocacy: Public awareness of brain cancer is on the rise, thanks to media campaigns and advocacy initiatives. This heightened awareness contributes to early detection and a growing demand for diverse treatment options. Advocacy groups are actively striving to enhance treatment accessibility and tackle issues impacting both patients and their families.

Rising Demand for Personalized Medicine: A growing understanding of cancer genomes and tumor variety is fuelling interest in personalized medicine and providing the way to more specialized treatment approaches. With this strategy, specific mutations or pathways within patients' malignancies can be precisely targeted, potentially improving treatment outcomes. One of the main factors driving market expansion in Spain is the country's aggressive investment in customized medicine research and its application to clinical settings.

Market Restraints

Regulatory Hurdles: The rigorous regulatory demands and approval procedures may present obstacles in the development and introduction of novel drugs for brain cancer treatment, potentially causing delays in their market entry.

Limited Efficacy of Current Treatments: The effectiveness of current treatments for brain cancer might be constrained, emphasizing the necessity for groundbreaking innovations to markedly enhance patient outcomes. This constraint could potentially influence the market prospects of presently available drugs.

High Development Costs: The research and development costs associated with creating effective brain cancer treatment drugs can be substantial. Companies may face financial constraints in funding extensive clinical trials and obtaining necessary approvals.

Healthcare Policies and Regulatory Landscape

In Spain, the regulatory body in charge of guaranteeing the effectiveness, security, and caliber of pharmaceuticals, including treatment drugs, is the Spanish Agency for Medicines and Health Products (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS). The national healthcare system in Spain, which offers coverage to all citizens, has an impact on healthcare policies. Healthcare policies are governed by the decentralized Systema Nacional de Salud (SNS) in Spain, where healthcare services are managed by local regions. Drug access, pricing, and reimbursement policies are governed by regulations as well, and these decisions are frequently made at the national and regional levels.

Competitive Landscape

Key Players

• Roche
• Merck & Co.
• Bristol Myers Squibb
• Novartis
• Pfizer
• AstraZeneca
• Eli Lilly
• Sanofi
• Takeda Pharmaceutical
• AbbVie